The association between hepatitis C infection and survival after orthotopic liver transplantation.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Gastroenterology

• Publication date

  2002-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/GAST.2002.32418PMID 11910340
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modelling Survival Data in Medical Research

  2004cited by this paper
• Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation

  2000cited by this paper
• Hepatitis C–induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate

  2000cited by this paper
• Pretransplantation hepatitis C virus quasispecies may be predictive of outcome after liver transplantation

  2000cited by this paper
• HCV-related fibrosis progression following liver transplantation: increase in recent years.

  2000cited by this paper
• Natural history of clinically compensated hepatitis C virus–related graft cirrhosis after liver transplantation

  2000cited by this paper
• Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience.

  1999cited by this paper
• Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin.

  1999cited by this paper
• European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.

  1999cited by this paper
• High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes

  1999cited by this paper
• An Empirical Comparison of Several Clustered Data Approaches Under Confounding Due to Cluster Effects in the Analysis of Complications of Coronary Angioplasty

  1999cited by this paper
• Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.

  1999cited by this paper
• Diagnostic tests for hepatitis C.

  1999cited by this paper
• Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection.

  1998cited by this paper
• Predictors of patient and graft survival following liver transplantation for hepatitis C

  1998cited by this paper
• Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS Liver Transplant Registry.

  1998cited by this paper
• Long‐term outcome of hepatitis C virus infection after liver transplantation

  1997cited by this paper
• Diagnostic tests for hepatitis C

  1997cited by this paper
• Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.

  1997cited by this paper
• Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients

  1996cited by this paper
• Clinical and histologic patterns of early graft failure due to recurrnet hepatitis C in four patients after liver transplantation.

  1996cited by this paper
• Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation

  1996cited by this paper
• Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization.

  1996cited by this paper
• Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation

  1996cited by this paper
• Long-term outcome of hepatitis C infection after liver transplantation.

  1996cited by this paper
• Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation

  1995cited by this paper
• The course of hepatitis C virus infection after liver transplantation

  1994cited by this paper
• Hepatitis C viral infection after orthotopic liver transplantation.

  1994cited by this paper
• Proportional hazards tests and diagnostics based on weighted residuals

  1994cited by this paper
• Modelling Survival Data in Medical Research.

  1994cited by this paper
• Antibody response to core, envelope and nonstructural hepatitis C virus antigens: Comparison of immunocompetent and immunosuppressed patients

  1993cited by this paper
• Hepatitis C viral infection in liver transplant recipients

  1992cited by this paper
• Recurrence of hepatitis C virus infection after orthotopic liver transplantation

  1991cited by this paper
• Statistical Analysis with Missing Data.

  1989cited by this paper
• Statistical Analysis with Missing Data

  1988cited by this paper
• Statistical Analysis With Missing Data

  1988cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Lesson learnt from 60 years of liver transplantation: Advancements, challenges, and future directions

  2025cites this paper
• 2025 KASL clinical practice guidelines for management of hepatitis C

  2025cites this paper
• Segurança e Eficácia dos Antivirais de Ação Direta no Tratamento da Hepatite C em Transplantados

  2025cites this paper
• Safety and Efficacy of Direct-Acting Antivirals in the Treatment of Hepatitis C in Transplant Recipients

  2025cites this paper
• Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation

  2024cites this paper
• Insights into Synonymous Codon Usage Bias in Hepatitis C Virus and Its Adaptation to Hosts

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• Real-world effectiveness and safety of direct-acting antivirals for the treatment of hepatitis C virus in kidney and liver transplant recipients: experience of a large transplant center in Brazil

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• Managing HBV and HCV Infection Pre- and Post-liver Transplant.

  2023cites this paper
• Complications in Post-Liver Transplant Patients

  2023cites this paper
• A systematic review of direct acting antiviral therapies in hepatitis C virus‐negative liver transplant recipients of hepatitis C‐viremic donors

  2022cites this paper
• A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database

  2022cites this paper
• Drug–Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir–Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection

  2021cites this paper
• HCV and Liver Transplantation

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• From Heresy to Standard of Care: A Virologic Journey

  2021cites this paper
• Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Orthotopic liver transplantation for patients with end-stage alcohol-related liver disease and severe acute alcohol-related hepatitis

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Transplantation of liver from hepatitis C–infected donors to hepatitis C RNA–negative recipients: Histological and virologic outcome

  2021cites this paper
• Donation After Circulatory Death Yields Survival Rates Similar to Donation After Brain Death Liver Transplant, Which Effectively Expands the Donor Pool.

  2021cites this paper
• Distinct Immune Imprints of Post–Liver Transplantation Hepatitis C Persist Despite Viral Clearance

  2021cites this paper
• Orthotopic liver transplantation for patients with end-stage alcohol-related liver disease and severe acute alcohol-related hepatitis: a concise review.

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Are Hepatitis C Positive Female Liver Transplant Recipients Still at Increased Risk for Graft Failure? Reexamining the Disparity in the Modern Era of Direct-acting Antiviral Agents

  2021influential citation
• Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis

  2021cites this paper
• "Safe use of livers from deceased donors older than 70 years in recipients with HCV cirrhosis treated with direct-action antivirals. Retrospective cohort study".

  2021cites this paper
• Elastography in Liver-Transplanted Patients

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Green analytical method for the determination of sofosbuvir, ledipasvir, ribavirin and complex silymarin flavonoids simultaneously in biological fluids

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Outcomes of Non-alcoholic Steatohepatitis following Liver Transplantation. An Updated Meta-analysis and Systematic Review.

  2021cites this paper
• Indication for Liver Transplantation After Direct-Acting Agents in the Treatment of Patients With Hepatitis C.

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• From hepatitis A to E: A critical review of viral hepatitis

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• The Reliability of Fibro-test in Staging Orthotopic Liver Transplant Recipients with Recurrent Hepatitis C

  2020cites this paper
• Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation results from the CO23 ANRS CUPILT study

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Direct-acting antivirals (DAAs): the answer to hepatitis C virus reactivation after organ transplantation?

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma

  2020cites this paper
• Sonography of liver transplantation

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• EASL recommendations on treatment of hepatitis C - Final update of the series.

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Efficacy and safety of sofosbuvir-containing regimens in patients with chronic hepatitis C virus infection after liver transplantation: a meta-analysis

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Multiple imaging modality-guided radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma in special locations.

  2020cites this paper
• Lower Likelihood of Post-transplant Graft Failure, Death, and Retransplantation in the Era of Direct-Acting Antivirals.

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Impact of Early Initiation of Direct-Acting Antiviral Therapy in Thoracic Organ Transplantation from Hepatitis C Virus Positive Donors.

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Management of end-stage alcohol-related liver disease and severe acute alcohol-related hepatitis: position paper of the Italian Society on Alcohol (SIA).

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper